Phase 2 N=25 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=597 Glass Ionomer Sealant and Fluoride Varnish Study to Prevent Early Childhood Caries
Dental Caries
Primary: Caries Incidence — 137; 123 Participants
Phase 2 N=79 Minocycline Study in Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms — 51.5; 30.6; 36.2 Units on a scale *days
Phase 2 N=44 High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Melanoma
Primary: Objective Response Rate — 25 percentage of participants
Phase 2 N=10 Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants
Phase 2 N=70 Safety and Efficacy of Nemolizumab in PN
Prurigo Nodularis
Primary: Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) Score at Week 4 Using Last Observation Carried Forward (LOCF) Approach…
Phase 2 N=30 ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
Diffuse Large B Cell Non-Hodgkin Lymphoma
Primary: Number of Participants With Dose Limiting Toxicity Events — 0; 0; 0 Participants
Phase 2 N=80 Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Heart Failure Acute · Heart Failure，Congestive · Heart Failure; With Decompensation
Primary: Dyspnea — 1264; 1650 mmxh — p=0.18
Phase 2 N=66 Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
Schizophrenia · Schizo-affective Disorder
Primary: Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone
Phase 2 N=3 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis
Primary: Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 — NA; NA percentage
Phase 2 N=99 Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion
Urinary Tract Infections · Catheter Infection · Catheter-Related Infections
Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants
Phase 2 N=256 Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
Gastroesophageal Reflux
Primary: Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment — 36.54; 36.69; 38.43 percentage of HBF 24-hour periods — p=0.7480
Phase 2 N=170 Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen
Chronic Hepatitis B
Primary: Difference in Percentage of Patients Between Treatment and Comparator Arm Reaching a ≥ 1log10 Decline of Quantitative HBsAg After 48 Weeks — 26; 1; 80; 53 Participants…
Phase 2 N=29 Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Leukemia
Primary: Overall Response Rate (ORR) — 0; 3 Participants